AJMC October 30, 2019
Laura Joszt

As the number of high-cost orphan drugs and gene and cell therapies continues to grow, there will be a greater need for alternative payment models (APMs) to help figure out the best way to pay for these treatments.

During a session at AMCP Nexus 2019, panelists discussed how value-based contracts can affect different stakeholders, the value of these payment models, some challenges to implementing APMs, and some examples of success happening in the market.

There are really 4 stakeholders surrounding the patient, explained Roger Longman, MA, chairman, Real Endpoints. These stakeholders are:

  • Payers, who want to simply pay for what works based on the demonstrated value;
  • Manufacturers, who want to lower the barriers to their drugs and differentiate from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Employer, Govt Agencies, Healthcare System, Insurance, Medical Devices, Patient / Consumer, Payment Models, Pharma, Pricing / Spending, Provider, Trends, Value Based
Transforming The Narrative On Homelessness
How Hospitals Can Avoid a Price Transparency Audit: Part III
Models adjusting for geography show racial gaps in telehealth use
CDC: Thanks in part to fewer COVID-19 deaths, life expectancy rises slightly from 2021 to 2022
Federal Legislation And State Policy Efforts Promote Access To And Use of Discounted Cash Prices

Share This Article